Bausch Health Companies Inc
BHCBausch Health Companies Inc. is a global pharmaceutical company specializing in the development, manufacturing, and marketing of a broad range of healthcare products, including prescription medications, over-the-counter products, and medical devices. Founded in 2010 and headquartered in Laval, Quebec, Bausch Health focuses on areas such as eye health, dermatology, gastrointestinal, and neurology, aiming to improve patient outcomes through innovative therapies.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 22, 2010 | $1.00 | 2010-11-10 | 2010-11-15 |
| October 4, 2010 | $0.10 | 2010-08-30 | 2010-09-01 |
| July 5, 2010 | $0.10 | 2010-05-28 | 2010-06-02 |
| April 5, 2010 | $0.09 | 2010-03-04 | 2010-03-08 |
| January 4, 2010 | $0.09 | 2009-11-30 | 2009-12-02 |
Dividends Summary
- Consistent Payer: Bausch Health Companies Inc has rewarded shareholders with 22 dividend payments over the past 5 years.
- Total Returned Value: Investors who held BHC shares during this period received a total of $6.43 per share in dividend income.
- Latest Payout: The most recent dividend of $1.00/share was paid 5687 days ago, on December 22, 2010.
- Dividend Growth: Since 2005, the dividend payout has grown by 100.0%, from $0.50 to $1.00.
- Dividend Reliability: BHC has maintained or increased its dividend for 7 consecutive payments.
Company News
The hepatic encephalopathy market is projected to grow at 1.2% CAGR through 2036, valued at USD 900 million in 2025. Growth is driven by rising prevalence of chronic liver diseases, improved early diagnosis awareness, and emerging therapies from companies like Vedanta Biosciences, Yaqrit Discovery Ltd, and others. The US dominates with 60% market...
Bausch Health Companies reported Q1 2026 earnings that beat analyst expectations with $2.52 billion in revenue (up 12% YoY) and non-GAAP net income of $0.78 per share (up 35% YoY), exceeding consensus estimates of $2.42 billion and $0.68 per share respectively. The company maintained its full-year 2026 guidance and highlighted 12 consecutive quar...
The pheochromocytoma and paraganglioma (PCPG) market is projected to grow at 7.3% CAGR through 2036, driven by emerging therapies including radioligand treatments, HIF-2α inhibitors, and targeted agents. The market was valued at USD 300 million in 2025 across seven major markets, with the US accounting for 67% of the market. Key companies includ...
The global dermatology devices market is projected to grow from $14.4 billion in 2024 to $25.6 billion by 2030, with a CAGR of 10.4%. Growth is driven by rising skin cancer incidence, aging populations, aesthetic procedure demand, and technological innovations including picosecond lasers and 3D bioprinting. North America leads with 52.3% market s...
The global scar treatment market is projected to grow from USD 26.60 billion in 2025 to USD 56.30 billion by 2033, with a CAGR of 9.91%. Growth is driven by increasing awareness of advanced cosmetic and reconstructive procedures, rising prevalence of acne, surgical, and traumatic scars, and technological advancements in minimally invasive treatme...
